Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Executive Summary
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
You may also be interested in...
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.
US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It
Agency willing to talk to generic sponsors about complex product issues, but it can avoid the resource-intensive process by updating product-specific development guidances.